2022-08-20 高雄萬豪酒店 10F皇喜會議室 10D-1
| 時間 | 主題 | 講者 | 座長 | 摘要 | 簡報 |
|---|---|---|---|---|---|
10:30 ~ 10:40 |
PD02-1: Mir-299-3p inhibits cell proliferation, motility and invasion through VEGFA in upper tract urothelial carcinoma |
王建勝 |
蔡曜州, 鍾旭東 |
||
10:40 ~ 10:50 |
PD02-2: The prognostic significance of ROR2 expression in patients with urothelial carcinoma |
李威明 |
蔡曜州, 鍾旭東 |
||
10:50 ~ 11:00 |
PD02-3: Decreased Dehydrogenase/Reductase 2(DHRS2) expression is associated with poor prognosis in urothelial carcinoma patients |
吳奕儒 |
蔡曜州, 鍾旭東 |
||
11:00 ~ 11:10 |
PD02-4: Outcomes of chemotherapy agents as subsequent replacements for discontinued Bacillus Calmette-Guerin bladder instillation in bladder cancer |
林柏廷 |
蔡曜州, 鍾旭東 |
||
11:10 ~ 11:20 |
PD02-5: Predictive factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma |
陳震亞 |
蔡曜州, 鍾旭東 |
||
11:20 ~ 11:30 |
PD02-6: The therapeutic potential of chemoradiotherapy combine with regional hyperthermia therapy for locally advanced bladder cancer- phase III clinical trial preliminary data report |
王大齊 |
蔡曜州, 鍾旭東 |